Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Kathryn A. Bylow MD

Assistant Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology
Program: Hematology

Member of the Cancer Center


  • Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). (Atallah E, Bylow K, Troy J, Saber W) Curr Hematol Malig Rep 2014 Mar;9(1):57-65 PMID 24398726
  • Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. (Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M) Cancer 2014 Mar 1;120(5):692-701 PMID 24249435
  • The Vulnerable Elders Survey-13 predicts mortality in older adults with later-stage colorectal cancer receiving chemotherapy: a prospective pilot study. (Ramsdale E, Polite B, Hemmerich J, Bylow K, Kindler HL, Mohile S, Dale W) J Am Geriatr Soc 2013 Nov;61(11):2043-4 PMID 24219208
  • Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study. (Bylow K, Hemmerich J, Mohile SG, Stadler WM, Sajid S, Dale W) Urology 2011 Apr;77(4):934-40 PMID 21269665
  • WITHDRAWN: Cognitive effects of androgen deprivation therapy in an older cohort of men with prostrate cancer. (Mohile SG et al.) Crit Rev Oncol Hematol 2009 May 14: PMID 19446466
  • Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study. (Dale W, Hemmerich J, Bylow K, Mohile S, Mullaney M, Stadler WM) J Clin Oncol 2009 Apr 1;27(10):1557-63 PMID 19255325
  • Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. (Bylow KA, Atkins MB, Posadas EM, Stadler WM, McDermott DF) Clin Genitourin Cancer 2009 Jan;7(1):39-42 PMID 19213667
  • Management of complications of androgen deprivation therapy in the older man. (Mohile SG, Mustian K, Bylow K, Hall W, Dale W) Crit Rev Oncol Hematol 2009 Jun;70(3):235-55 PMID 18952456
  • Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. (Bylow K, Dale W, Mustian K, Stadler WM, Rodin M, Hall W, Lachs M, Mohile SG) Urology 2008 Aug;72(2):422-7 PMID 18561991
  • Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review. (Bylow K, Mohile SG, Stadler WM, Dale W) Cancer 2007 Dec 15;110(12):2604-13 PMID 17960609
  • Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. (Ryan CW, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO, Vogelzang NJ) BJU Int 2007 Jul;100(1):70-5 PMID 17552955
  • A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. (Mohile SG, Bylow K, Dale W, Dignam J, Martin K, Petrylak DP, Stadler WM, Rodin M) Cancer 2007 Feb 15;109(4):802-10 PMID 17219443
  • Temporal arteritis: The importance of recognizing senescent changes versus quiescent disease in a temporal artery biopsy. (Bylow KA, Brauner DJ) J Am Geriatr Soc 2006 Dec;54(12):1959-60 PMID 17198518
  • Grants and Awards

  • Phase I/II Study of BNC105P in Combination w/Everolimus or Following Everolimus for Progressive Metastatic Clear Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors: Hoosier Oncology Group GU09-145 (#9305399 03/10/2011 - 02/24/2015) Sponsor: Hoosier Oncology Group, Inc.
  • A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects with Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease (#9305487 09/14/2011 - 12/31/2016) Sponsor: Janssen Pharmaceutical Inc
  • A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) vs. Mitoxantrone Plus Prednisone in Men with Previously Treated Symptomatic Castration-resistant Prostate Cancer (#9306034 02/08/2013 - 02/07/2018) Sponsor: Exelixis, Inc.
  • Use of B-Hydroxy-B-Methylbutyrate to Counteract Loss of Muscle Mass and Strength in Older Men with Recurrent Prostate Cancer Started on Androgen Deprivation Therapy (#9950022 06/01/2011 - 05/31/2015) Sponsor: State of Wisconsin
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men w Non-Metastatic (M0) Castration-Resistant Prostate Cancer (#9306826 10/28/2014 - 05/27/2019) Sponsor: Aragon Pharmaceuticals, Inc
  • Phase 1, Open-Label Multicentre Dose-Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Pts with Advanced Solid Tumours where the Androgen Receptor Pathway is a Potential Factor (#9306917 03/02/2015 - 03/01/2018) Sponsor: SCRI Development Innovations, LLC
  • Phase II Randomized Trial of Genomically Directed Therapy After Preoperative Chemo in Triple Negative Breast Cancer (#9306740 10/16/2014 - 10/15/2017) Sponsor: Hoosier Oncology Group, Inc.
  • Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastasis (#9306083 04/11/2013 - 04/10/2016) Sponsor: Covance, Inc.
  • A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination with OGX-427 in Patients with Relapsed or Refractory Metastatic Urothelial Carcinoma after Receiving a Platinum-containing Regimen (#9306200 09/05/2013 - 09/04/2016) PI of A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination with OGX-427 in Patients with Relapsed or Refractory Metastatic Urothelial Carcinoma after Receiving a Platinum-containing Regimen (#3306200)
  • Last update: 06/03/2014